HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Toxicity Testing For Topical Drugs, Sunscreens Included, On Tap In US FDA Workshop

This article was originally published in The Pink Sheet & The Rose Sheet

Executive Summary

While FDA does not identify specific product types on the agenda for its public workshop on approaches in skin toxicity testing for topical drug products, advocacy and trade groups anticipate sunscreen ingredient testing could be among the discussion topics. Product expansions have been stifled by regulatory concerns, drawing particular attention from the public health community.

You may also be interested in...



US FDA's Sunscreen Progress Gets Dim Review From Congressional Appropriators

House and Senate appropriators' take note that US FDA has not approved an additional OTC sunscreen ingredient since the 2014 passage of the Sunscreen Innovation Act.

Exclusivity Period Allowed By OTC Monograph Reform Likely Up To Conference Committee

Next step for OTC monograph reform legislation is Senate consideration; market exclusivity periods are likely focus of House/Senate conference. Separate bill to allow consumers to use health savings accounts to buy OTC drugs without a doctor's prescription clears House Ways and Means panel.

Feminine Cleanser Marketing Never Without Challenges; Now The Category Has FDA’s Attention

FDA is investigating use of certain ingredients in feminine cleansing and hygiene products, according to its fiscal 2019 budget justification. The agency’s work could draw unfavorable attention to a category that already comes under fire regularly for alleged body shaming and disproportionate ill effects on women of color, among other accusations.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

RS122659

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel